Abstract：Objective: To discuss the curative effect ofgamma globulin combined with prednisone in treatment myasthenia gravis and its effect on serum Acetylcholine receptor antibody (AchRAb), transforming growth factor-β1 (TGF-β1) and complement. Methods: 99 patients with myasthenia gravis who treated from January 2014 to April 2018 in our hospital, according to the simple random number table method these patients were divided into 56 control group and 43 observation group. The control group was treated with prednisone, and the observation group was treated with gamma globulin on the basis of the control group. Then clinical efficacy,absolute score of muscular weakness, levels of AchRAb, TGF-β1, complement at different time points,and adverse reactions occurred in both groups were compared. Results: After treatment, the total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). Before treatment, absolute score, levela of AchRAb, TGF-β1 and complement in both group were no statistically significant difference (P>0.05). 3 months after treatment and at the end of treatment, the absolute score of muscular weakness and level of AchRAb in both groups were decreased, and the levels of TGF-β1 and complement in the observation group were lower than those in the control group, while those in the observation group were higher than those in the control group, there were statistically significant differences in absolute scores, AchRAb, TGF- 1 and complement levels between the two groups in terms of treatment methods and treatment time (P<0.05). Fatigue, appetite loss, blood pressure drop and weight gain occurred in both groups, and there was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The curative effect of gamma globulin combined with prednisone in the treatment of myasthenia gravis is superior to that of prednisone, which can reduce the serum AchRAb level, promote the expression of TGF-β1 and complement, and is safe and reliable.
[1] Chen W, Li FF, Li C, et al. Artemisinin ameliorates the symptoms of experimental autoimmune myasthenia gravis by regulating the balance of TH1 cells, TH17 cells and Treg cells[J].Biol Regul Homeost Agents,2018,32(5):1217~1223. [2] 许会军,陈晓芳,刘鹏,等.重症肌无力的发病机制[J].中国临床神经科学,2014,22(6):677~679,685. [3] 郭东,李聪,万婷,等.丙种球蛋白联用泼尼松治疗重症肌无力临床疗效[J].检验医学与临床,2017,14(20):3041~3043. [4] Wang MG, Huang XX, Yao D, et al. Effect of glucocorticoid combined with gamma globulin in treatment of children with myasthenia gravis and its effects on immune globulin and complement of children[J]. Eur Rev Med Pharmacol Sci,2016,20(11):2404~2408. [5] 李尊波,熊葶,刘建军,等.短程大剂量糖皮质激素冲击联合其他免疫抑制剂治疗重症肌无力的疗效观察[J].中国神经免疫学和神经病学杂志,2015,22(1):16~19. [6] Abuzinadah AR, Jabari D, Jawdat O, et al. Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis[J].Clin Neuromuscul Dis,2018,20(2):49~59. [7] 王芳.静脉注射免疫球蛋白联合利妥昔单抗治疗重症肌无力危象的近远期疗效研究[J].中西医结合心脑血管病杂志,2017,15(21):2782~2785. [8] 杨俊超,文颖娟.重症肌无力实验动物模型的研究进展[J].医学综述,2015,21(19):3466~3469. [9] 王银萍.实验性自身免疫性重症肌无力动物模型研究[J].长春中医药大学学报,2015,31(6):1282~1285.
2019, Vol. 25 
冀公网安备13080202000677号